Capecitabine Plus Bevacizumab as First-Line Therapy for Patients with Metastatic Colorectal Cancer and Poor Performance Status

Yasufumi Yamada, Kazuhiko Yoshimatsu, Hajime Yokomizo, Sachiyu Okayama, Masaya Satake, Arika Ida, Hiroyuki Maeda and Shunichi Shiozawa

Department of Surgery, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan

Background: The benefit of chemotherapy for patients with metastatic colorectal cancer has not been established.

Methods: We retrospectively evaluated the effectiveness of chemotherapy with capecitabine and bevacizumab for patients with a performance status (PS) of 3.

Results: Seven patients were included; median age was 82 years (range, 65-91 years). Response was not ascertained; however, the disease control rate was 83.3%. Median PFS and OS were 10.0 and 25.8 months, respectively. Hand-foot syndrome was the most common toxicity observed (3 patients; 42.9%). Grade 3 toxicity was observed in 1 patient with proteinuria and 1 with hypertension.

Conclusion: Chemotherapy using capecitabine and bevacizumab appeared to improve OFS and OS for patients with poor PS. However, care must be taken not to impose unnecessary burdens on patients with poor PS. (J Nippon Med Sch 2021; 88: 496-499)

Key words: capecitabine, bevacizumab, metastatic colorectal cancer, performance status

Introduction
The AVEX study of adults older than 70 years showed that a capecitabine + bevacizumab (Bmab) regimen significantly prolonged progression-free survival (PFS), as compared with capecitabine monotherapy, and was effective and tolerable as first-line therapy for elderly patients. However, that study enrolled only 1 patient with poor performance status (PS). Several clinical guidelines consider single administration of fluoropyrimidine, with or without molecularly targeted drugs, as inappropriate for intensive therapy in patients with metastatic colorectal cancer (mCRC). In addition, the capecitabine + Bmab regimen has been used in elderly patients, in those with poor PS, and in those who decline aggressive chemotherapy. However, the benefits of chemotherapy are unclear for elderly patients with mCRC and those with poor PS. This study evaluated the effects of capecitabine + Bmab therapy for mCRC patients with poor PS.

Patients and Methods

Patients
We enrolled 7 of 21 patients with mCRC consecutively started on capecitabine + Bmab as first-line chemotherapy from April 2014 through December 2017 at the Department of Surgery of Tokyo Women’s Medical University Medical Center East. The general inclusion criteria of this region in the institute are if the assessment of a patient’s clinical condition for chemotherapy is vulnerable or patient’s request. All 7 patients presented with an Eastern Cooperative Oncology Group (ECOG) PS of 3. Clinicopathological factors and treatment outcomes were retrospectively analyzed. Written informed consent was obtained from all patients before participation in the
Capcitabine Plus Bmab for PS3 Patients

Table 1 Characteristics of Patients

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Gender</th>
<th>T</th>
<th>N</th>
<th>Primary site</th>
<th>Metastatic site</th>
<th>CEA</th>
<th>Alb</th>
<th>CRP</th>
<th>NLR*</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>82</td>
<td>F</td>
<td>T4a</td>
<td>N2</td>
<td>T</td>
<td>Peritoneal dissemination</td>
<td>148.4</td>
<td>3.5</td>
<td>0.52</td>
<td>2.43</td>
<td>SD</td>
</tr>
<tr>
<td>2</td>
<td>84</td>
<td>M</td>
<td>T3</td>
<td>N1</td>
<td>Rb</td>
<td>Local recurrence</td>
<td>6.6</td>
<td>3.1</td>
<td>1.30</td>
<td>4.12</td>
<td>SD</td>
</tr>
<tr>
<td>3</td>
<td>65</td>
<td>M</td>
<td>T4a</td>
<td>N0</td>
<td>RS</td>
<td>Bone</td>
<td>3.6</td>
<td>4.2</td>
<td>0.05</td>
<td>3.30</td>
<td>SD</td>
</tr>
<tr>
<td>4</td>
<td>91</td>
<td>F</td>
<td>T3</td>
<td>N0</td>
<td>A</td>
<td>Peritoneal dissemination</td>
<td>4.5</td>
<td>3.5</td>
<td>0.51</td>
<td>1.92</td>
<td>SD</td>
</tr>
<tr>
<td>5</td>
<td>76</td>
<td>F</td>
<td>T4b</td>
<td>N1</td>
<td>S</td>
<td>Peritoneal dissemination</td>
<td>77.3</td>
<td>3.2</td>
<td>0.27</td>
<td>2.48</td>
<td>PD</td>
</tr>
<tr>
<td>6</td>
<td>81</td>
<td>F</td>
<td>T3</td>
<td>N1</td>
<td>C</td>
<td>Liver, Peritoneal dissemination</td>
<td>9.7</td>
<td>3.8</td>
<td>0.31</td>
<td>5.46</td>
<td>SD</td>
</tr>
<tr>
<td>7</td>
<td>83</td>
<td>M</td>
<td>T4a</td>
<td>N0</td>
<td>T</td>
<td>Lung</td>
<td>7.4</td>
<td>4.6</td>
<td>0.20</td>
<td>2.15</td>
<td>SD</td>
</tr>
</tbody>
</table>

* Neutrophil-to-lymphocyte ratio

Table 2 Treatment cycles and response

<table>
<thead>
<tr>
<th>Number of treatment cycles</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 (1-27)</td>
<td>SD 5</td>
</tr>
<tr>
<td>1</td>
<td>PD 1</td>
</tr>
</tbody>
</table>

Disease control rate 83.3%

Results

Patient Characteristics

The characteristics of the enrolled patients are summarized in Table 1. Median age was 82 years (range, 65-91), and 5 patients were older than 80 years. The participants comprised 3 men and 4 women. The colon and rectum were the primary sites of cancer in 5 and 2 patients, respectively. Six patients were histologically diagnosed with differentiated tumors. On the basis of the Japanese Classification of Colorectal Carcinoma, 3 tumors were classified as N0, 3 as N1, and 1 as N2. Furthermore, 3 patients presented with metastasis to the peritoneum and 1 each to a local site, liver, lung, and bone.

Response

The median number of capcitabine + Bmab treatment cycles was 7 (range, 1-17 cycles). No complete or partial response was observed in any patient. The best response during treatment was stable disease, in 5 patients. Thus, the disease control rate was 83.3%, excluding patients who failed in 1 course (Table 2). No improvement in PS was observed in any patient during chemotherapy.

Outcomes

Median PFS was 10.0 months (Fig. 1). The most common reason for discontinuation of the regimen was disease progression, in 5 patients. The other reasons were a further decrease in PS, in 1 patient, and nonadherence, in 1 patient (Table 3). Three patients underwent second-line therapy: 1 with S-1 and irinotecan + Bmab, 1 with irinotecan + Bmab, and 1 with trifluridine/tipiracil (TAS102). The median OS
for the enrolled patients was 25.8 months (Fig. 2).

Dose Intensity
Two of 7 patients did not require dose reduction of capecitabine or Bmab. One patient required a 25% dose reduction for capecitabine after the start of chemotherapy. The other patient ultimately required a 50% reduction of capecitabine and treatment cessation, because of toxicity. Most patients required extension of the rest period. Overall relative dose intensity was 69.5% for capecitabine and 68.4% for Bmab.

Adverse Drug Reactions
The toxicities encountered during the regimen are summarized in Table 4. The most common toxicity, of any grade, was hand-foot syndrome, in 3 patients (42.8%). The most common grade 3/4 toxicities were proteinuria and hypertension, in 2 patients (28.6%); 1 patient developed proteinuria and 1 developed hypertension (both grade 3). Because few hematological toxicities were observed, the capecitabine + Bmab regimen was considered well-tolerated. One patient discontinued treatment after the first course because of a further decrease in PS as a result of bowel obstruction. No patient discontinued treatment because of drug toxicity.

Discussion
Although the response rate for the capecitabine + Bmab regimen has been reported to be greater than 30%, no response was observed in any of the present patients. Furthermore, the present disease control rate was better than that in the AVEX study and similar to that in the MAX study. In the current study, median PFS after first-line treatment was 10.0 months. Feliu et al. reported a median PFS and OS of 10.8 and 18 months, respectively, for 59 mCRC patients aged 70 years or older treated with capecitabine + Bmab as first-line therapy. The OS in the present study was 25.8 months.

The good outcomes for the present PS3 patients may be attributable to the absence of multiple organ metastases, which may have resulted in a lower tumor burden. Additionally, cases considered resectable if patients had good PS might be included. Moreover, basic activities of daily living and nutritional status were maintained in some patients, even when they required prolonged first-line chemotherapy. Toxicity in the current study was significantly lower than in previous studies. These findings suggest that the capecitabine + Bmab regimen is tolerable for patients with poor PS.

In conclusion, this study found that PFS and OS were favorable in patients with poor PS, despite an inadequate

Fig. 1 Kaplan-Meier curve of time to treatment failure.

Fig. 2 Kaplan-Meier curve of overall survival.

Table 3 Reasons for discontinuation and second-line treatment

<table>
<thead>
<tr>
<th>Reason</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease progression</td>
<td>5</td>
</tr>
<tr>
<td>Worsened performance status</td>
<td>1</td>
</tr>
<tr>
<td>Patient decision</td>
<td>1</td>
</tr>
<tr>
<td>Second-line treatment</td>
<td>No 5</td>
</tr>
<tr>
<td></td>
<td>Yes 3</td>
</tr>
<tr>
<td></td>
<td>IRIS + Bmab 1</td>
</tr>
<tr>
<td></td>
<td>Irinotecan + Bmab 1</td>
</tr>
<tr>
<td></td>
<td>TAS102 1</td>
</tr>
</tbody>
</table>
Capcitabine Plus Bmab for PS3 Patients

Table 4 Adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0

<table>
<thead>
<tr>
<th>All G</th>
<th>G1</th>
<th>G2</th>
<th>G3</th>
<th>G4</th>
<th>G3/4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>7</td>
<td>5</td>
<td>2</td>
<td>0</td>
<td>2 (15.4)</td>
</tr>
</tbody>
</table>

Hematologic toxicities

- Neutropenia
  - 1

Non-hematologic toxicities

- General fatigue
  - 1
- Mucositis oral
  - 1
- Diarrhea
  - 1
- Hypertension
  - 1
- Hand-foot syndrome
  - 3
- Proteinuria
  - 1
- Hemorrhage
  - 1
- Dysgeusia
  - 2
- AST
  - 1

anti-tumor response. Adverse events were considered tolerable because only a few toxicities were noted. These findings suggest that capcitabine + Bmab might yield favorable PFS and OS for vulnerable mCRC patients with poor PS.

Conflict of Interest: The authors declare no conflicts of interest associated with this manuscript.

References


Journal of Nippon Medical School has adopted the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) for this article. The Medical Association of Nippon Medical School remains the copyright holder of all articles. Anyone may download, reuse, copy, reprint, or distribute articles for non-profit purposes under this license, on condition that the authors of the articles are properly credited.